Chimeric vaccines
CA 2446462 C · Owner: Marques, Ernesto Jr. · Inventors: Marques, Ernesto Jr.; August, Thomas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment irrespective of whether , the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally the chimeric protein comprises a , trafficking domain of an endocytic receptor (e.g. such as DEC-205 or gp200- MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 5, 2002 and granted December 22, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.